Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 12, 2026
TickeronGET DAILY SIGNALS
Manulife Financial (MFC): Q1 2026 Earnings Preview and What Investors Should Watch

Manulife Financial (MFC): Q1 2026 Earnings Preview and What Investors Should Watch

Key Takeaways

  • Analysts expect Q1 2026 core EPS of C$1.09, up 10% from C$0.99 in Q1 2025.
  • 12 analysts contribute to the consensus, with estimates ranging from C$0.99 to C$1.14.
  • Manulife's stock has gained over 10% year-to-date, outperforming broader markets amid strong insurance sales momentum.
  • Focus on Asia segment growth, core ROE (return on equity), and LICAT ratio (life insurance capital adequacy test).
  • Historical beats in recent quarters, including Q4 2025 EPS of US$0.80 vs. US$0.76 expected.
  • Earnings due after market close on May 13, 2026, with conference call on May 14.

Understanding the Earnings Context

Manulife Financial (MFC), one of the leading global life insurers, will report its Q1 results for the period ended March 31, 2026, on May 13. From what I see, this release will provide insight into whether the company can sustain the momentum from 2025's record core earnings of C$7.5 billion, which rose 3% on a constant exchange rate basis. With shares up over 10% year-to-date and trading near 52-week highs around US$40, investors are looking for confirmation of strong sales in Asia, growth in wealth management fees, and resilient margins despite shifting interest rates. In a competitive insurance market, MFC's emphasis on high-return areas like Asia and its global wealth and asset management (WAM) business sets it apart. Key indicators such as APE (annualized premium equivalent) sales and new business CSM (contractual service margin) will reveal demand trends, while the LICAT ratio will highlight capital strength supporting dividends and buybacks.

What to Expect from Q1 Earnings

The consensus points to Q1 2026 core EPS of C$1.09, marking 10% growth from C$0.99 in Q1 2025 (estimated at C$0.98, with a slight beat on the actual). This forecast draws from 12 analysts, whose estimates span C$0.99 on the low end to C$1.14 on the high. Revenue figures aren't widely available for the quarter, though full-year 2026 projections sit around C$50 billion. I think core earnings growth will hinge on insurance new business—APE sales jumped 37% last year—and fee-related flows in WAM.

MFC has shown a mixed but generally positive history of beating estimates: Q4 2025 EPS came in at US$0.80 versus US$0.76 expected, Q3 2025 beat by US$0.10, though Q1 2025 was a slight miss. Post-earnings stock moves have been muted on average, with attention turning to guidance on core ROE above 15% and LICAT over 130%.

Market Sentiment Ahead of Earnings

Heading into this report, sentiment around MFC feels cautiously optimistic—shares are up 10% year-to-date, and analyst ratings lean toward buy. Options pricing suggests a modest ~4% move post-earnings, indicating tempered expectations. Potential risks include foreign exchange headwinds from a strong CAD, elevated credit losses, or weaker demand in Asia. Past beats have tended to lift the stock, but misses like Q2 2025 triggered pullbacks. The current elevated implied volatility captures the usual pre-earnings caution.

AI Screener: My Go-To Tool for Comparison

I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. This AI-powered tool scans stocks and ETFs based on technical patterns, fundamentals, trends, volatility, and AI signals, letting you filter by industry, market cap, indicators, and more. It surfaces trade ideas and opportunities faster than manual reviews, which has been helpful in my analysis. If you're screening for insurance names or similar setups, it's worth exploring.

Looking Ahead: Key Metrics and Outlook

After Q1 results, one thing that stands out is the updated guidance on full-year core EPS growth and mid-teens ROE targets. MFC's 10.2% dividend increase in 2025 to C$0.485 per share reflects confidence in capital returns, alongside ongoing NCIB buybacks.

Asia continues to be pivotal, with prior surges in APE sales pointing to lasting demand. I'll be watching new business CSM and NBV (new business value) for signs of profitability in these growth markets. In WAM, fee revenue and AUM growth amid equity market rallies will matter a great deal.

Capital metrics remain a strength—LICAT at 137% in recent quarters and solid leverage—but keep an eye on ECL (expected credit losses) and investment spreads in this rate environment. Broader industry factors like reinsurance and regulations could affect margins. Future catalysts include Q2 results in August and updates on Asia expansion; I'm watching this closely.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: MFC

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


MFC's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for MFC turned positive on October 15, 2026. Looking at past instances where MFC's MACD turned positive, the stock continued to rise in 29 of 45 cases over the following month. The odds of a continued upward trend are 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MFC as a result. In 47 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.

MFC moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MFC crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 40%.

Following a +1.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where MFC advanced for three days, in 223 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 204 of 354 cases where MFC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.

Bearish Trend Analysis

The 10-day RSI Indicator for MFC moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 24 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 65 cases where MFC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MFC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.

MFC broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MFC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.587) is normal, around the industry mean (1.339). P/E Ratio (12.062) is within average values for comparable stocks, (19.975). Projected Growth (PEG Ratio) (0.876) is also within normal values, averaging (0.463). Dividend Yield (0.032) settles around the average of (0.048) among similar stocks. P/S Ratio (1.780) is also within normal values, averaging (1.303).

The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are MetLife (NYSE:MET), Prudential Financial (NYSE:PRU), Lincoln National Corp (NYSE:LNC), Genworth Financial (NYSE:GNW).

Industry description

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

Market Cap

The average market capitalization across the Life/Health Insurance Industry is 18.76B. The market cap for tickers in the group ranges from 228.36K to 140.68B. CILJF holds the highest valuation in this group at 140.68B. The lowest valued company is GWGHQ at 228.36K.

High and low price notable news

The average weekly price growth across all stocks in the Life/Health Insurance Industry was 2%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was -4%. CNO experienced the highest price growth at 7%, while AAME experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Life/Health Insurance Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was 9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 72
Price Growth Rating: 56
SMR Rating: 91
Profit Risk Rating: 60
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
MFC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of life and health insurance and reinsurance services

Industry LifeHealthInsurance

Industry
Life Or Health Insurance
Address
200 Bloor Street East
Phone
+1 416 926-3000
Employees
27000
Web
https://www.manulife.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.
Consensus estimates call for Q3 FY2026 revenue of approximately $3.37 billion, in line with the company's guidance midpoint of $3.35 billion. Non-GAAP earnings per share (EPS) expected at $9.16, edging above the guided midpoint of $9.08.